← Association for Accessible Medicines
USTRNonrulemakingUSTR-2018-0036

Negotiating Objectives for a U.S.-United Kingdom Trade Agreement

RIN
—
Last modified
Feb 22, 2019
Comment window
closed 2751d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Jan 15, 2019 and Jan 15, 2019. 81 other organizations filed here. The comment window closed 2751d ago.

What Association for Accessible Medicines filed (1)

Jan 15, 2019· Comment from Association for Accessible Medicines· USTR-2018-0036-0063

In response to the above-referenced notice, the Association for Accessible Medicines (AAM) hereby submits a request to testify and written comments in preparation for the negotiation of a U.S.-United Kingdom (UK) Trade Agreement. AAM represents manufacturers and distributors of generic pharmaceuticals and biosimilar medicines. Generic medicines make up 90% of prescriptions dispensed in the United States, but only 23% of total drug spending. In 2016, AAM members manufactured over 61 billion doses of prescription medicines in the United States at 149 facilities in 16 states. Our members manufacture generic and biosimilar medicines in the U.S. for domestic use and for export markets, including the UK. AAM requests the opportunity to provide testimony at the January 29, 2018, hearing. The witness will be: Jeffrey K. Francer Senior Vice President & General Counsel Association for Accessible Medicines 601 New Jersey Avenue, NW Suite 850 Washington, DC 20001 202-249-7100 AAMs testimony will address the issues covered in the attached comments.

View on regulations.gov →

Abstract

The Trade Policy Staff Committee (TPSC) US-UK public hearing scheduled for January 29, 2019 at 9:30 am at the US International Trade Commission location has changed to the Office of the U.S. Trade Representative, 1724 F Street, NW, Washington, DC 20508

View on regulations.gov →

Co-filers (81)

See everyone who commented →